Skip to main content

Table 1 Baseline characteristics and medications

From: Thyroid function, glycemic control, and diabetic nephropathy in patients with type 2 diabetes over 24 months: prospective observational study

 

Control

T2DM

Characteristics

Male

115

124

Female

110

76

Total

225

200

Age

51.0 ± 11.2

68.3 ± 10.3**

Height(cm)

164.0 ± 8.6

161.3 ± 9.0**

Weight (kg)

62.4 ± 12.6

68.8 ± 45.9*

BMI (kg/m2)

23.1 ± 3.5

26.3 ± 17.1**

Systolic BP (mmHg)

125.0 ± 16.3

133.9 ± 19.3**

Diastolic BP (mmHg)

75.4 ± 11.4

73 ± 11.6*

HbA1c(%)

5.4 ± 0.3

7.2 ± 0.8**

FPG (mg/dl)

91.6 ± 8.5

147.9 ± 43.4*

IRI (µU/ml)

6.8 ± 3.8

17.6 ± 32.3**

CPR (ng/ml)

1.5 ± 0.6

2.5 ± 1.6**

T-CHO (mg/dl)

217.7 ± 41.3

190.7 ± 36.2**

TG (mg/dl)

106.7 ± 86.8

138.3 ± 88.2**

HDL (mg/dl)

68.9 ± 15.6

54 ± 14.1**

LDL (mg/dl)

124.5 ± 32.9

107.2 ± 26.8*

Medications

 

number

(%)

number

(%)

For hypertension

 

any

28

12.4

104

52.0**

ARB

16

7.1

79

39.5**

ACEI

0

0

5

1.5*

CaB

24

10.7

65

32.5**

α-blocker

1

0.4

5

2.5

β-blocker

4

1.8

4

2.0

diuretics

1

0.4

5

2.5

For dyslipidemia

  

any

14

6.2

79

39.5*

statins

11

4.9

73

36.5*

ezetimib

1

0.4

5

2.5

fibrate

1

0.4

5

2.5

vitamin E

2

0.9

0

0

For diabetes

   

any

-

-

176

88

DPPIVI

-

-

116

56.9

biguanide

-

-

91

45.5

SU

-

-

69

34.5

αGI

-

-

30

15

SGLT2

-

-

16

8

TZD

-

-

5

2.5

glinide

-

-

5

2.5

insulin

-

-

46

23

GLP1

-

-

7

3.5

  1. **: P < 0.01, *: P < 0.05
  2. ARB: angiotensin II receptor blocker, ACEI: angiotensin converting enzyme inhibitors
  3. CaB: calcium channel blocker, DPIVI: dipeptidyl peptidase-4 inhibitor
  4. SU: sulfonyl urea, αGI: α-glycosidase inhibitor
  5. TZD: thiazolidinedione, GLP1: glucagon-like peptide 1 analog